Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:48:45.741Z.
Consensus retrieved: 2026-10-06T15:26:34.873Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:48:45.741Z.
Quote observation: 2026-10-06T16:45:29.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5f06b8b41e0980caada53469fccf6de542fb6b04de3a821a907ddebd40a39f21
Forward PE Ratio (N/A) = Dated Quote Price ($1.59) / Consensus Forward EPS ($-0.66)
FORWARD PE RATIO
N/A
ProKidney Corp.
Market Cap
$534.64M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| ProKidney Corp. (PROK) | $534.64M | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $538.18M | N/A |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $538.80M | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $541.20M | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $525.25M | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $544.79M | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $522.46M | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $550.22M | N/A |
| Altimmune, Inc. (ALT)vs › | $517.30M | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $513.27M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.59, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.66 | $-0.67 – $-0.65 | 3 | n/m |
| 2027-12-31 | $-0.66 | $-1.22 – $-0.40 | 4 | n/m |
| 2028-12-31 | $-0.38 | $-0.47 – $-0.32 | 3 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
